title: Therapeutic potential of riboflavin, niacin and ascorbic acid on carbohydrate metabolizing enzymes in secondary endometrial carcinoma bearing rats.
abstract: Curative potential of riboflavin, niacin and ascorbic acid against tamoxifen mediated endometrial carcinoma was established by studies on carbohydrate metabolizing enzymes. The enzymes investigated were glycolytic enzymes namely, hexokinase; aldolase; phosphoglucoisomerase and the gluconeogenic enzymes namely, glucose-6-phosphatase and fructose-1, 6-biphosphatase in endometrial carcinoma bearing rats. A significant increase in glycolytic enzymes and a subsequent decrease in gluconeogenic enzymes were observed in plasma, liver and kidney of endometrial carcinoma animals. The administration of riboflavin (45 mg/kg bw/day), niacin (100 mg/kg bw/day) and ascorbic acid (200 mg/kg bw/day) along with tamoxifen (45 mg/kg bw/day) caused a significant decrease in the activity of glycolytic enzymes and a significant increase in the activities of gluconeogenic enzymes to near normal levels in experimental animals. Our results suggest that riboflavin, niacin and ascorbic acid have potential combination therapy against tamoxifen mediated secondary endometrial carcinoma in experimental rats. However, there were no deleterious side effects observed in combinants alone treated animals.
authors.affiliation: Department of Medical Biochemistry, Dr. ALM Post - Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, 600 113, India. ssundravelibms@yahoo.co.in
authors.forename: Sengodan
authors.initials: S
authors.lastname: Sundravel
authors.forename: Palanivel
authors.initials: P
authors.lastname: Shanthi
authors.forename: Panchanadham
authors.initials: P
authors.lastname: Sachdanandam
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D050260:Carbohydrate Metabolism / Q000187:drug effects*; D002277:Carcinoma / Q000188:drug therapy / Q000201:enzymology* / Q000556:secondary; D004353:Drug Evaluation, Preclinical; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D005260:Female; D009362:Neoplasm Metastasis; D009525:Niacin / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D012256:Riboflavin / Q000494:pharmacology* / Q000627:therapeutic use; D013629:Tamoxifen / Q000378:metabolism / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D013629:Tamoxifen; D009525:Niacin; D001205:Ascorbic Acid; D012256:Riboflavin